TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17882582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional organ preservation treatment)
Study: 14997188
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with radiotherapy
Study: 10975783
Drug: Two-week dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week dual therapy (lansoprazole 30 mg plus amoxycillin 1 g bid for two weeks)
Study: 10975783
Drug: One-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week triple therapy (lansoprazole 30 mg plus amoxycillin 1 g plus tinidazole 500 mg bid for one week plus lansoprazole qd for an additional week)
Study: 10975783
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (after one year follow-up)
Study: 10975783
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (after one year follow-up)
Study: 1592541
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg oral sustained release theophylline twice a day
Study: 22445423
Drug: Active model
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active model group (n=176) with self-evaluation kit and treatment of metronidazole 500 mg twice daily for 7 days
Study: 14623548
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (exemestane, anastrozole)
Study: 14623548
Drug: Combination strategies
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination strategies of gonadotrophin agonists and aromatase inhibitors
Study: 14623548
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of aromatase inhibitors
Study: 10714753
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (somatotropin, 0.222 mg/kg/week, divided into 3 doses each week)
Study: 8928847
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg in 10 ml saline)
Study: 4058956
Drug: i.v. naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. naloxone (0.04 mg/kg)
Study: 30241688
Drug: SL edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL edaravone 30 mg
Study: 30241688
Drug: IV edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV edaravone 30 mg infusion
Study: 30241688
Drug: Both SL
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SL and IV administration
Study: 15164501
Drug: Long-term morphine-clopheline
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term morphine-clopheline epidural analgesia
Study: 15164501
Drug: Conventional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesia (intravenous injection of morphine)
Study: 8989246
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy at doses of 0.6 and 1.2 IU/day
Study: 2955253
Drug: Low MW
Normalized name: low-substituted hydroxypropyl cellulose (11% hydroxypropyl; 100000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low MW heparin (Kabi 2165) administered as 5000 or 10,000 anti-factor Xa units, s.c., half an hour prior to dialysis
Study: 2955253
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of 5000 anti-factor Xa units of low MW heparin given i.v.
Study: 2955253
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of low MW heparin at 5000 anti-factor Xa units bolus plus 1500 anti-factor Xa units/h
Study: 2955253
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of low MW heparin at approximately 4000 anti-factor Xa units bolus plus 750 anti-factor Xa units/h
Study: 25013996
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (LGH) therapy
Study: 22699446
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell (PCECV) rabies vaccine
Study: 22699446
Drug: Purified verocell
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified verocell rabies vaccine (PVRV)
Study: 15676050
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 400 microg
Study: 20015921
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 100 and 200 microg
Study: 18809612
Drug: Hypnosis intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnosis intervention (five weekly sessions)
Study: 15757817
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulfate ointment (15% in urea) applied twice daily for 20 days
Study: 15757817
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate (1 ml intradermally every other day for 20 days)
Study: 11828262
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (dl‐alpha‐tocopherol) 1000 mg/day for 3 months
Study: 10049268
Drug: Fasting conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting conditions (twice)
Study: 10049268
Drug: Antacids (aluminum-magnesium)
Normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (aluminum-magnesium)
Study: 7589655
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) initiated in early follicular phase
Study: 7589655
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) initiated in midluteal phase
Study: 7589655
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) initiated in late luteal phase
Study: 31701170
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (for selected patients with PD-L1 CPS ≥1 and ≥20)
Study: 17868011
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment over a 6-week course
Study: 17868011
Drug: Prophylactic drug
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic drug treatment over a 6-month period
Study: 8972953
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic EMLA cream
Study: 1479198
Drug: Combined hyperthermia
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hyperthermia (HT) and radiation therapy (XRT)
Study: 6428504
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% carbon dioxide and 65% oxygen
Study: 6428504
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% carbon dioxide and 65% oxygen preceded by 60 mg propranolol
Study: 25613235
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy
Study: 9540025
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 or 100 mg t.i.d.)
Study: 8294388
Drug: Combined SSRI
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined SSRI (sertraline or fluvoxamine) with moclobemide
Study: 8294388
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 to 800 mg/day) with sertraline (25 to 200 mg/day)
Study: 8294388
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 to 800 mg/day) with fluvoxamine (50 to 200 mg/day)
Study: 2660873
Drug: Sultamicillin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sultamicillin (375 mg)
Study: 2660873
Drug: Trimethoprim/sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg)
Study: 4261553
Drug: Spectinomycin 2
Normalized name: spectinomycin 2 g intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin 2 g
Study: 4261553
Drug: Spectinomycin 4
Normalized name: spectinomycin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin 4 g
Study: 24885005
Drug: Video-based feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based feedback of public oral presentations
Study: 24885005
Drug: Classical oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical oral presentations without feedback (Control)
Study: 17962424
Drug: Carvedilol controlled-release
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol controlled-release 40 mg with ethanol (approximately 38 g)
Study: 17962424
Drug: Carvedilol controlled-release
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol controlled-release alone
Study: 17962424
Drug: Carvedilol controlled-release
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol controlled-release with ethanol 2 hours after administration
Study: 17962424
Drug: Carvedilol controlled-release
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol controlled-release alone or with ethanol
Study: 16236169
Drug: Steroid-naïve atopic
Normalized name: Atopica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-naïve atopic asthmatic children
Study: 16236169
Drug: Atopic asthmatic
Normalized name: Atopica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopic asthmatic children receiving inhaled corticosteroids
Study: 12404872
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of antivenom
Study: 12404872
Drug: 2 to
Normalized name: T2 toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 to 5 ml of antivenom
Study: 12404872
Drug: No antivenom
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antivenom administration
Study: 2697725
Drug: 1% fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% fusidic acid viscous eye drops, instilled twice daily for 7 days
Study: 2697725
Drug: rifamycin eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifamycin eye drops, four times daily for 7 days
Study: 12484
Drug: Oxypertine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxypertine (10 mg every 12 hours, 20 mg daily)
Study: 7104467
Drug: Conventional 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 4 mg tablet administered every 6 hours
Study: 7104467
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release 8 mg barrier coated-bead capsule administered every 12 hours
Study: 7104467
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release 8 mg repeat action tablet administered every 12 hours
Study: 25853935
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (levosimendan + nesiritide)
Study: 23200590
Drug: Domiciliary non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary non-invasive ventilation in addition to long-term oxygen therapy (LTOT)
Study: 15342839
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 33 microg/kg/day for 3 years
Study: 11180040
Drug: ADL 8-2698
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ADL 8-2698 (4 mg) with intravenous morphine (0.05 mg x kg(‐1))
Study: 11180040
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.05 mg x kg(‐1))
Study: 11180040
Drug: ADL 8-2698
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ADL 8-2698 (4 mg) with intravenous morphine (0.15 mg/kg)
Study: 9895052
Drug: Mechanical lithotripsy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical lithotripsy (ML)
Study: 8043892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion for improvement of glycaemic control
Study: 8043892
Drug: Reduced insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced insulin dose
Study: 8043892
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin dose
Study: 31178499
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence for phosphate binders
Study: 31178499
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence for antidiabetic medications
Study: 31178499
Drug: Reason for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reason for missed dose
Study: 31178499
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for oral medication (mental burden present)
Study: 31178499
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for oral medication (no mental burden)
Study: 31178499
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for oral medication (neither)
Study: 31178499
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of mental burden by eliminating 1 medication
Study: 26433819
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice-daily) and Trametinib (2 mg once-daily)
Study: 26433819
Drug: Vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (960 mg twice-daily)
Study: 21863678
Drug: Mometasone spray
Normalized name: mometasone Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone spray
Study: 21863678
Drug: NSS (Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS (Normal Saline Solution)
Study: 19856872
Drug: Complex compound
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex compound of Cu(II) (dinitrate (V) di (3,4,5‐trimethyl‐N1‐pyrazol‐kappaN2) copper (II))
Study: 19856872
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Cu(II) compound)
Study: 16960473
Drug: Citalopram (a
Normalized name: citalopram (as citalopram hydrobromide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (a selective serotonin reuptake inhibitor)
Study: 16960473
Drug: Buspirone (5-HT1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5-HT1a receptor-specific challenge)
Study: 8818855
Drug: Comparator agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator agents (amoxycillin, co-amoxiclav, cefixime, cefaclor, clarithromycin, erythromycin, penicillin V, cloxacillin, or roxithromycin)
Study: 23410792
Drug: Comparator agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator agents
Study: 2004477
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 micrograms i.v. in bolus) plus rhEPO (40 U/kg in constant infusion for 30 min)
Study: 18495964
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (100 mg of elemental iron)
Study: 18495964
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (various doses ranging from 20 to 500 mg)
Study: 8555470
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (45 mg/kg/d for 4 consecutive days)
Study: 6823889
Drug: Consideration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consideration of contamination iron in iron absorption measurements
Study: 23144438
Drug: Preperitoneal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preperitoneal continuous wound infusion (CWI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Study: 23144438
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Study: 23144438
Drug: Preperitoneal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preperitoneal continuous wound infusion (CWI)
Study: 18928218
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (1 mg/ml applied at the site of discectomy for 5 minutes)
Study: 16086983
Drug: Internet-administered self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet-administered self-help plus minimal therapist contact via e-mail
Study: 16086983
Drug: Traditional individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional individual cognitive behaviour therapy
Study: 8349938
Drug: Methacholine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine nasal challenge (1 to 25 mg)
Study: 3770869
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplementation (1 g/day)
Study: 22767199
Drug: Intratympanic steroids
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroids (4 injections of 0.3 ml dexamethasone at 8 mg/ml and 0.2 ml hyaluronic acid 0.2%)
Study: 22767199
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (prednisolone, hydroxyethyl starch, pentoxyfylline)
Study: 17963825
Drug: Monthly fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monthly fluorouracil (1000 mg/m2/day i.v. for 5 days) plus cisplatin (20 mg/m2/day i.v.)
Study: 17963825
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (30 mg/m2 i.v.)
Study: 17963825
Drug: Monthly fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monthly fluorouracil plus cisplatin
Study: 31164277
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin
Study: 9760148
Drug: mini‐ICE/ICE chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini‐ICE/ICE chemotherapy
Study: 9760148
Drug: 5 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 + 2/7 + 3 chemotherapy
Study: 25832443
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of DHA supplementation for two weeks
Study: 12743539
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus 5‐methoxytryptamine (5‐MTT) 1 mg/day orally
Study: 12743539
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin plus etoposide)
Study: 3978014
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% cream (Eutectic Mixture of Local Anaesthetics)
Study: 30880074
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens extract (320 mg)
Study: 30281182
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen with a bolus of 3 μg/kg fentanyl (group FENTANYL)
Study: 25250780
Drug: Testoviron depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testoviron depot (i.m.: 100 mg/10 days)
Study: 25250780
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (50 mg/die)
Study: 25250780
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks)
Study: 22765768
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg alone
Study: 22765768
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg after pre-treatment with phenytoin 150 mg
Study: 16220082
Drug: INH-A21 750
Normalized name: COXSACKIEVIRUS A21
DrugBank: Gebasaxturev (DB17296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH-A21 750 mg/kg
Study: 7589766
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sustained-release isradipine
Study: 7589766
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lacidipine
Study: 2289389
Drug: Tetracycline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 mg, five-day course every six hours)
Study: 2289389
Drug: Ampicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (250 mg, five-day course every six hours)